Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early Coronary Atherosclerosis in Women With Previous Preeclampsia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of Sudden Cardiac Death in the European Union

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Contemporary Management of Severe Symptomatic Aortic Stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Left atrial contractile strain predicts recurrence of atrial tachyarrhythmia after catheter ablation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Global and regional wall motion abnormalities and incident heart failure in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The metabolic signature of cardiovascular disease and arterial calcification in patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GALACTIC-HF Investigators
Vis graf over relationer

BACKGROUND: In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint (PCE) of time-to-first heart failure event or cardiovascular death in patients with heart failure and reduced ejection fraction (EF) (≤35%).

OBJECTIVES: The purpose of this study was to evaluate the influence of baseline EF on the therapeutic effect of omecamtiv mecarbil.

METHODS: Outcomes in patients treated with omecamtiv mecarbil were compared with placebo according to EF.

RESULTS: The risk of the PCE in the placebo group was nearly 1.8-fold greater in the lowest EF (≤22%) compared with the highest EF (≥33%) quartile. Amongst the pre-specified subgroups, EF was the strongest modifier of the treatment effect of omecamtiv mecarbil on the PCE (interaction as continuous variable, p = 0.004). Patients receiving omecamtiv mecarbil had a progressively greater relative and absolute treatment effect as baseline EF decreased, with a 17% relative risk reduction for the PCE in patients with baseline EF ≤22% (n = 2,246; hazard ratio: 0.83; 95% confidence interval: 0.73 to 0.95) compared with patients with EF ≥33% (n = 1,750; hazard ratio: 0.99; 95% confidence interval: 0.84 to 1.16; interaction as EF by quartiles, p = 0.013). The absolute reduction in the PCE increased with decreasing EF (EF ≤22%; absolute risk reduction, 7.4 events per 100 patient-years; number needed to treat for 3 years = 11.8), compared with no reduction in the highest EF quartile.

CONCLUSIONS: In heart failure patients with reduced EF, omecamtiv mecarbil produced greater therapeutic benefit as baseline EF decreased. These findings are consistent with the drug's mechanism of selectively improving systolic function and presents an important opportunity to improve the outcomes in a group of patients at greatest risk. (Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329).

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind78
Udgave nummer2
Sider (fra-til)97-108
Antal sider12
ISSN0735-1097
DOI
StatusUdgivet - 13 jul. 2021

Bibliografisk note

Published by Elsevier Inc.

ID: 69610850